Insider Trading March 31, 2026

UTI Legal Chief Disposes $888,115 in Shares as Company Posts Mixed Q1 Results

Executive Vice President and Chief Legal Officer Christopher Kevane sold 23,654 shares on March 27, 2026; company posts slight EPS miss but revenue beat

By Jordan Park UTI
UTI Legal Chief Disposes $888,115 in Shares as Company Posts Mixed Q1 Results
UTI

Christopher E. Kevane, Executive Vice President and Chief Legal Officer of Universal Technical Institute (NYSE:UTI), executed a sale of 23,654 shares on March 27, 2026, according to a Form 4 filing. The transaction totaled $888,115 at a weighted average price of $37.5461. The sale accompanies a recent week-long share decline and follows the company’s mixed first-quarter fiscal 2026 results that included a small earnings per share shortfall and a revenue beat. Truist Securities reiterated a Buy rating and $40 price target, and the company elected three Class I directors at its annual meeting.

Key Points

  • Christopher E. Kevane sold 23,654 shares of Universal Technical Institute on March 27, 2026, for a total of $888,115 at a weighted average price of $37.5461.
  • Universal Technical Institute’s fiscal 2026 Q1 results included EPS of $0.23 (a 4.17% negative surprise) and revenue of $220.8 million, above the $216.81 million expected.
  • Truist Securities maintained a Buy rating and $40 price target, while the company elected three Class I directors—Robert T. DeVincenzi, Jerome A. Grant, and Shannon L. Okinaka—at its annual meeting.

Christopher E. Kevane, who serves as Executive Vice President and Chief Legal Officer at Universal Technical Institute (NYSE:UTI), reported the sale of 23,654 shares of the company’s common stock on March 27, 2026, as disclosed in a Form 4 filing with the Securities and Exchange Commission.

The shares were disposed of at a weighted average price of $37.5461, bringing the total transaction value to $888,115. Individual sale prices in the reported trades ranged from $37.16 to $37.79. Following the disposition, Kevane is recorded as directly owning 83,521 shares of Universal Technical Institute.

UTI shares have experienced a 7.7% decline over the past week, though they remain 38% higher year-to-date. On valuation metrics, the company currently trades at a price-to-earnings ratio of 37.26 and carries a market capitalization of $2.04 billion. According to InvestingPro analysis included in the company’s recent summaries, UTI appears overvalued relative to its Fair Value estimate and is listed among stocks on the Most Overvalued list. The InvestingPro commentary also notes that investors can access 10 additional InvestingPro Tips and expanded financial metrics to assist in evaluating the stock’s outlook.

In corporate results disclosed recently, Universal Technical Institute reported its fiscal 2026 first-quarter earnings, delivering mixed outcomes. The company posted earnings per share of $0.23, narrowly missing the expected $0.24, which represents a 4.17% negative surprise versus expectations. Revenue for the quarter came in at $220.8 million, exceeding the anticipated $216.81 million.

Following the quarterly disclosure, Truist Securities reiterated its Buy rating on the stock and maintained a $40.00 price target, citing a solid start to the fiscal year and an expectation for acceleration in student enrollment starts. Truist also referenced positive enrollment data from a competitor as supportive of Universal Technical Institute’s growth outlook.

Separately, the company conducted its Annual Meeting of Stockholders, during which three Class I Directors were elected to serve three-year terms. The directors elected were Robert T. DeVincenzi, Jerome A. Grant, and Shannon L. Okinaka. The director elections and the company results are among a series of recent updates concerning Universal Technical Institute.


Clear summary

Kevane sold 23,654 shares on March 27, 2026, at a weighted average price of $37.5461 for $888,115; he now directly owns 83,521 shares. UTI posted Q1 fiscal 2026 EPS of $0.23 versus $0.24 expected and revenue of $220.8 million versus $216.81 million expected. Truist reiterated a Buy rating with a $40 target and three Class I directors were elected at the annual meeting.

Risks

  • Short-term share price volatility - UTI stock fell 7.7% over the past week, which could affect investor sentiment in the education and specialty training sector.
  • Valuation concerns - InvestingPro analysis indicates UTI appears overvalued relative to its Fair Value estimate, placing it on a Most Overvalued list and signaling valuation risk for equity investors.
  • Earnings sensitivity - A small EPS miss (EPS $0.23 vs $0.24 expected, a 4.17% negative surprise) highlights the company’s sensitivity to quarterly results, which can impact market reaction in the education services sector.

More from Insider Trading

ArrowMark Financial Director Buys 1,500 Shares as Company Launches Rights Offering Mar 31, 2026 Strawberry Fields REIT Director Acquires $17,465 Stake; Company Announces Dividend and Executive Pay Changes Mar 31, 2026 Edgewise Therapeutics CMO Disposes Shares While Exercising Options Amid Positive Trial News Mar 31, 2026 Platinum Equity Disposes of 1.35M Ingram Micro Shares in $28.8M Trade Mar 31, 2026 Adaptive Biotechnologies President Disposes of $751k in Stock While Exercising Options Mar 31, 2026